Urinary Actin, as a Potential Marker of Sepsis-related Acute Kidney Injury (NCT04968262) | Clinical Trial Compass
CompletedNot Applicable
Urinary Actin, as a Potential Marker of Sepsis-related Acute Kidney Injury
Hungary84 participantsStarted 2016-01-01
Plain-language summary
In our study, 17 septic, 43 sepsis-related acute kidney injury and 24 control patients were enrolled. Blood and urine samples were collected at the intensive care unit from acutely diagnosed septic and sepsis-related acute kidney injury patients at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up. Patients with malignancies needing palliative care, end-stage renal disease or kidney transplantation were excluded. Not more than one sample (venous blood, midstream spot urine) was collected from control patients. Serum and urinary actin levels were determined by quantitative Western blot. Urinary actin concentrations were expressed as µg/L, while serum actin levels were expressed as mg/L. Data were compared with laboratory and clinical parameters. Patients were categorized by the Sepsis-3 definitions and 30-day mortality data were investigated.
Who can participate
Age range
18 Years – 90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Sepsis
* Sepsis-related acute kidney injury
Exclusion Criteria:
* malignancies needing palliative care
* end-stage renal disease
* kidney transplantation
* under 18 years of age
* unobtainable consent
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study is already completed — has any data been published yet, and if so, what did the results show about whether urinary or serum actin levels could reliably predict kidney injury in sepsis patients?
2Since this was an observational study measuring actin in urine and blood rather than testing a new treatment, how might findings from this trial actually change the way my kidney function would be monitored if I develop sepsis?
3Given that this trial focused specifically on sepsis-related acute kidney injury, how does my own situation compare to the types of patients enrolled, and would those findings even be relevant to my case?
4Are there any current standard-of-care tests for early detection of sepsis-related kidney injury, and is actin measurement something my care team already uses or could use based on research like this?
5If actin turns out to be a useful early marker of kidney injury in sepsis, what would that mean in practical terms — would it lead to earlier treatment decisions, and are there clinical trials testing those next steps that might be worth looking into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.